<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Emerg Hosp Med Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Emerg Hosp Med Rep</journal-id><journal-title-group><journal-title>Current Emergency and Hospital Medicine Reports</journal-title></journal-title-group><issn pub-type="epub">2167-4884</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7296288</article-id><article-id pub-id-type="publisher-id">218</article-id><article-id pub-id-type="doi">10.1007/s40138-020-00218-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Infectious Disease (J Glauser, Section Editor)</subject></subj-group></article-categories><title-group><article-title>Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5860-5606</contrib-id><name><surname>Garber</surname><given-names>Boris</given-names></name><address><email>bgarber@metrohealth.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Glauser</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.67105.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2164 3847</institution-id><institution>MetroHealth Medical Center, </institution><institution>Case Western Reserve School of Medicine, </institution></institution-wrap>Cleveland, OH USA </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>6</month><year>2020</year></pub-date><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">We discuss and review new antimicrobials for treatment of bacterial, viral, fungal, and parasitic infections with indications, contraindications, and side effects for each. We will also review new information and indications on older agents that are relevant to clinical practice. Many of them may be unfamiliar to Emergency Physicians given their newness and at times hospital restrictions on their use. We also review some new promising agents that are not yet in the clinical pipeline.</p></sec><sec><title>Recent Findings</title><p id="Par2">As new antibiotics become available for clinicians to use, new information becomes available with respect to the drugs&#x02019; indications, efficacy, pathogen resistance, drug-drug interactions, and side effects.</p></sec><sec><title>Summary</title><p id="Par3">This article provides Emergency Department clinicians with a useful summary with new information on antibiotic use and recent research into agents which may become available.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotic</kwd><kwd>Resistance</kwd><kwd>Emergency</kwd><kwd>Development</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Antibiotics play a critical role in pharmacological management of Emergency Department patients presenting with apparent infectious disease [<xref ref-type="bibr" rid="CR1">1</xref>]. Antibiotic resistance development is a constant threat whether bacterial, viral, or fungal infections are concerned [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;, <xref ref-type="bibr" rid="CR3">3</xref>&#x02022;&#x02022;, <xref ref-type="bibr" rid="CR4">4</xref>]. As the new agents emerge and become available for clinical use, some antimicrobials lose effectiveness in some areas, while others become repurposed for a new indication. As multidrug resistant organisms increase in prevalence so is the need for antimicrobial polypharmacy early on in the management of the critically ill infected patients as well as prolonged courses of antibiotics, increasingly done on an outpatient basis [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;, <xref ref-type="bibr" rid="CR5">5</xref>]. Whether the Emergency Physician initiates treatment with an antimicrobial or is faced with a patient already taking one, a good understanding of shifting indications and contraindications for their use as well as drug-drug interactions and side effects continues to be important. Thus, staying abreast of new developments in infectious disease pharmaceutical armamentarium is a must for Emergency Medicine providers.</p></sec><sec id="Sec2"><title>Antibiotic Resistance</title><p id="Par5">Antibiotic-resistant bacteria continue to spread worldwide and are a persistent and severe health threat [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;] with morbidity and mortality increasing annually [<xref ref-type="bibr" rid="CR6">6</xref>]. There are multiple implications to physicians caring for patients with presentations concerning for infectious etiology, including the frequent need for early administration of multiple broad-spectrum antibiotics [<xref ref-type="bibr" rid="CR7">7</xref>]. Emergency Departments (EDs) are a common entry point for care for patients with a range of infectious diseases [<xref ref-type="bibr" rid="CR3">3</xref>&#x02022;&#x02022;], and ED physicians are on the front line for early and sometimes the only antibacterial therapy choice for these patients. Patients affected by extended spectrum &#x003b2;-lactamase&#x02013;producing and colistin-resistant <italic>Pseudomonas aeruginosa</italic>, carbapenem-resistant Enterobacteriaceae, methicillin-resistant <italic>Staphylococcus aureus</italic>, and drug-resistant <italic>Neisseria gonorrhoeae</italic> are encountered routinely in US Emergency Departments [<xref ref-type="bibr" rid="CR3">3</xref>&#x02022;&#x02022;]. Multidrug-resistant bacteria are affecting all populations and have been implicated even in neonatal sepsis requiring broader coverage in that patient group [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. It is important for ED providers to stay abreast of new therapies and concepts for these common and serious infections [<xref ref-type="bibr" rid="CR3">3</xref>&#x02022;&#x02022;].</p><p id="Par6">Antibiotic resistance development is not limited to bacteria; it involves all human pathogens. Pathogenic viruses have been known to become resistant to antivirals, with influenza A and B now commonly resistant to adamantane compounds and occasionally resistant to newer neuraminidase inhibitors [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Several antiviral compounds are being currently studied, including favipiravir and fludase with potential broad activity against many pathogenic RNA viruses such as Ebola, West Nile, rabies, and Zika in addition to influenza viruses [<xref ref-type="bibr" rid="CR10">10</xref>]. Another drug in clinical trials for influenza treatment is the neuraminidase inhibitor laninamivir which would be available as a nasal inhalation if approved [<xref ref-type="bibr" rid="CR11">11</xref>]. Nitazoxanide, an antiparasitic agent, used to treat cryptosporidium infection in AIDS patients is currently in trials for influenza treatment due to its apparent antiviral activity [<xref ref-type="bibr" rid="CR11">11</xref>]. Development of a more effective flu vaccine would do much to control influenza epidemics [<xref ref-type="bibr" rid="CR4">4</xref>]. As far as other viral diseases are concerned, Presatovir (GS-5806) is in trials for Respiratory Syncytial Virus infection [<xref ref-type="bibr" rid="CR11">11</xref>] and sofosbuvir, a drug previously approved for hepatitis C treatment, is in trials for treatment of Zika virus infection [<xref ref-type="bibr" rid="CR12">12</xref>]. While several new compounds are being studied, nothing new has become available for herpes virus illnesses since our last update[<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par7">Recently, several fungal disease outbreaks have been noted worldwide, ranging from keratitis in contact lens wearers to health care&#x02013;associated fungal infections with high mortality [<xref ref-type="bibr" rid="CR14">14</xref>]. Even as both invasive fungal infections and fungal resistance to currently limited antifungal drugs are becoming more common, and there are several molecules being studied for a number of fungal diseases [<xref ref-type="bibr" rid="CR15">15</xref>], there have not been any new antifungals approved for use in the USA since our last review in 2017. Some strains of <italic>Candida glabrata</italic> and <italic>auris</italic> implicated in disseminated disease are now multidrug resistant [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par8">The risk factors for infection with antibiotic-resistant bacteria include prior history of such an infection, chronic vascular access or chronic wound, and immunocompromised status stemming from chronic severe illness, malignancy, or primary immunologic defects [<xref ref-type="bibr" rid="CR3">3</xref>&#x02022;&#x02022;]. The need to use broad-spectrum antibiotics liberally and early unfortunately contributes to constantly emerging and evolving patterns of pathogen resistance [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Meanwhile, it has become a routine to use antibiotics liberally in situations where previously they were used infrequently, such as in patients with simple skin abscesses [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par9">Several pathogens were recently identified by the World Health Organization (WHO) as a critical priority, based on mortality, health care burden, and prevalence of resistance [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). The only two new antibacterial classes to be approved in the past 20&#x000a0;years&#x02014;lipopeptides and oxazolidinones&#x02014;are active against gram-positive pathogens [<xref ref-type="bibr" rid="CR1">1</xref>]. Quinolones, which first appeared in 1960, was the last novel class of antibiotics discovered to be active against gram-negative bacteria [<xref ref-type="bibr" rid="CR1">1</xref>]. Unfortunately many large pharmaceutical companies have limited investment into research in the past decade to discover new antibiotics in part due to negative financial incentives [<xref ref-type="bibr" rid="CR19">19</xref>]. By definition, antimicrobials are meant in general to cure disease rather than to be taken forever as, for example, medications to treat diabetes or hypertension. Furthermore, antimicrobial husbandry includes attempts to limit pathogen resistance by limiting the time course of treatment. Additionally, the FDA requires that new agents for use in simple infections show superiority, which would require a very large number of subjects enrolled in a study, since most of these infections resolve spontaneously [<xref ref-type="bibr" rid="CR19">19</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Critical priority bacteria according to WHO [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>&#x02022;]</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Multidrug-resistant tuberculosis, Carbapenem-resistant <italic>Acinetobacter baumannii</italic> and <italic>Pseudomonas aeruginosa</italic>, carbapenem and third-generation cephalosporin-resistant Enterobacteriaceae, vancomycin-resistant <italic>Enterococcus faecium</italic>, methicillin-resistant <italic>Staphylococcus aureus</italic>, clarithromycin-resistant <italic>Helicobacter pylori</italic>, fluoroquinolone-resistant Campylobacter spp., <italic>Neisseria gonorrhoeae</italic>, and <italic>Salmonella typhi</italic></td></tr></tbody></table></table-wrap></p><p id="Par10">Infections caused by resistant bacteria cause up to two-fold increase in adverse outcomes, even when the pathogen remains susceptible to the antibiotic but a higher minimal inhibitory concentration (MIC) is present [<xref ref-type="bibr" rid="CR20">20</xref>&#x02022;], especially if septic shock develops [<xref ref-type="bibr" rid="CR21">21</xref>]. This contributes to the need to use antibiotics in higher doses and for longer courses. There is evidence that even &#x003b2;-lactams in high concentrations can produce a range of organ toxicity especially in the critically ill, including neurologic, hepatic, renal, and hematological side effects whose frequency may be currently underestimated [<xref ref-type="bibr" rid="CR22">22</xref>]. Cephalosporins, including novel ones, appear to be proconvulsive, especially in patients with epilepsy [<xref ref-type="bibr" rid="CR22">22</xref>]. Not only are resistant bacteria more difficult to control in case of infection, but surgical antibiotic prophylaxis has also become less effective, as evidenced for example by an increase in bacteremia after invasive urological procedures despite fluoroquinolone prophylaxis [<xref ref-type="bibr" rid="CR20">20</xref>&#x02022;]. This is an important point to keep in mind for Emergency Department doctors when these patients present.</p><p id="Par11">Other important mechanisms for development and spread of resistant bacteria have been recently emphasized. For example, many bacteria and fungi have the ability to form biofilms by both free living and pathogenic species, thereby limiting local antibiotic penetration [<xref ref-type="bibr" rid="CR5">5</xref>]. Chronic infection in rhinosinusitis, purulent ulcers, and cystic fibrosis seem to be due to biofilms in large part [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;]. As another example, <italic>Pseudomonas aeruginosa</italic> resistance to fluoroquinolones may be induced by diltiazem, a commonly used calcium channel blocker [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;].</p><p id="Par12">Even when an antibiotic is withdrawn, or its use restricted, it does not guarantee that a bacterium will become susceptible to it again. Multidrug-resistant traits do not affect Gonorrhea biological fitness, so it persists despite the lack of antibiotic exposure selection pressure [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par13">Broad-spectrum antibiotic use puts patients at risk for developing <italic>Clostridium difficile</italic> colitis (CDI). A recent Cochrane review emphasized increased symptomatic cure with vancomycin when compared to metronidazole, fidaxomicin compared to vancomycin, and possibly teicoplanin compared to vancomycin [<xref ref-type="bibr" rid="CR24">24</xref>] in CDI patients. Importantly, no recent studies looked at optimal treatment of severe <italic>C. difficile</italic> colitis [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec3"><title>Conclusion</title><p id="Par14">Even though many clinicians are alarmed at the slow and uneven pace of the new antibiotics development [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;, <xref ref-type="bibr" rid="CR20">20</xref>&#x02022;], a good many antimicrobial agents are now on the market (Table <xref rid="Tab2" ref-type="table">2</xref>) as well as new anti-tuberculosis and antiviral medications (Table <xref rid="Tab3" ref-type="table">3</xref>) since our last paper was published. Opening up new indications for old antibiotics becomes an increasingly important topic (Table <xref rid="Tab4" ref-type="table">4</xref>) with a few stories of success over the years&#x02014;anti-community MRSA armamentarium includes doxycycline and trimethoprim-sulfamethoxazole, while the new research focuses on testing old antibiotics for <italic>Neisseria gonorrhoeae</italic> treatment and using anti-inflammatory properties of antibiotics in treatment of progressive degenerative neurological disorders. Several promising molecules are undergoing trials to establish their efficacy as therapeutic agents (Table <xref rid="Tab5" ref-type="table">5</xref>). Unfortunately, if the history is any guide, only select few will become available for use for an Emergency Physician any time soon [<xref ref-type="bibr" rid="CR2">2</xref>&#x02022;, <xref ref-type="bibr" rid="CR19">19</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Select new FDA-approved antibiotics on the market in the USA since year 2017 Google Scholar and Medscape Search [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug class</th><th>Names and notes</th><th>Indications</th><th>Select side effects</th><th>Comments</th></tr></thead><tbody><tr><td>Aminomethylcyclines</td><td>Omadacycline</td><td>Skin and soft tissue infections, pneumonia caused by Gram-positive pathogens including MRSA, <italic>S. pneumonia</italic> and VRE, some Gram negatives, Fragilis, Legionella, and Chlamydia</td><td>Similar to newer tetracyclines such as doxycycline</td><td>In trials for pneumonia treatment mortality rate was higher in omadacycline group</td></tr><tr><td>Tetracyclines</td><td>Sarecycline</td><td>Approved for treatment of acne vulgaris.</td><td>Similar to newer tetracyclines such as doxycycline</td><td/></tr><tr><td>Tetracyclines</td><td>Eravacycline</td><td>Complicated intraabdominal infections have broad-spectrum activity for treatment of Gram+ and Gram&#x02212; intraabdominal infections</td><td>Infusion site reaction, tetracycline class adverse reactions</td><td>Related to tigecycline. Not approved for urinary tract infections</td></tr><tr><td>Aminoglycoside</td><td>Plazomicin</td><td>Complicated UTI and ventilator-associated pneumonia [<xref ref-type="bibr" rid="CR28">28</xref>] caused by Gram-negative pathogens when no other treatment option exists</td><td>Acute kidney injury, especially in patients with renal disease. Aminoglycoside class adverse reaction including at times irreversible ototoxicity, especially in patients with family history of hearing problems and neuromuscular blockade, especially in patients with preexisting neuromuscular disorders</td><td/></tr><tr><td>Nitroimidazole</td><td>Pretomanid</td><td>Limited patient populations with extensively drug resistant or non-responsive with multidrug-resistant <italic>M. tuberculosis</italic> infection only in combination with bedaquiline and linezolid</td><td>Hepatotoxicity, myelosuppression, neurotoxicity, QT prolongation, lactic acidosis, multiple drug-drug interactions</td><td/></tr><tr><td>Fluoroquinolones</td><td>Delafloxacin [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>Broad spectrum including MRSA, other Gram positives and Gram negatives for skin and soft tissue infections</td><td>Carries the same black box warning as other fluoroquinolones, appears to have less QTc prolongation compared to other fluoroquinolones</td><td/></tr><tr><td>Rifamycins</td><td>Rifamycin</td><td>Traveler&#x02019;s diarrhea caused by noninvasive <italic>E. coli</italic> in adults</td><td>Dyspepsia; generally low risk of side effects</td><td>Not for patient with diarrhea associated with fever or bloody stools</td></tr><tr><td>Nitroimidazole</td><td>Secnidazole</td><td>Treatment of bacterial vaginosis</td><td>Candidal vulvovaginitis</td><td>Single-dose treatment</td></tr><tr><td>Carbapenem with &#x003b2; lactam inhibitor</td><td>Meropenem/vaborbactam</td><td>Complicated UTIs caused by Gram-negative organisms</td><td>Risk of seizures with meropenem in patients with CNS disorders, reduced valproic acid serum concentration</td><td/></tr><tr><td>Cephalosporin</td><td>Cefideracol [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>Complicated UTIs caused by MDR Gram negatives with no other option, has been used for treatment of ventilator-associated pneumonia [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td/><td>Increased mortality in critically ill patient with pneumonia or sepsis with carbapenem-resistant pathogens observed</td></tr><tr><td>Pleuromutilin</td><td>Lefamulin</td><td>Community-acquired pneumonia, active against S. pneumonia, H. flu, Legionella, C. pneumonia, MSSA, mycoplasma</td><td>Potential for QT prolongation, fetal toxicity, multiple drug-drug interactions</td><td>Oral and injectable formulations are available</td></tr><tr><td>Imipenem/cilastatin/relebactam</td><td>Carbapenem/dehydropeptidase inhibitor/B-lactamase inhibitor</td><td>Complicated UTIs and intraabdominal infection in patients where no alternative treatment is available</td><td>Risk of seizures with carbapenem antibiotics in patients with CNS disorders may decrease valproic acid serum concentrations</td><td/></tr></tbody></table><table-wrap-foot><p><italic>VRE</italic> vancomycin-resistant enterococcus, <italic>MDR</italic> multidrug resistant, <italic>MSSA</italic> methicillin-sensitive <italic>Staphylococcus aureus</italic>, <italic>MRSA</italic> methicillin-resistant <italic>Staphylococcus aureus</italic></p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Select new FDA-approved anti-tuberculosis drugs and antivirals on the market in the USA since year 2017</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug class</th><th>Names and notes</th><th>Indications</th><th>Side effects</th><th>Comments</th></tr></thead><tbody><tr><td>Antiviral protein inhibitor</td><td>Tecovirimat</td><td>Small pox in adults and children</td><td>Headache in healthy volunteers; hypoglycemia when combined with repaglinide</td><td>Available through Strategic national Stockpile. Unknown efficacy in humans</td></tr><tr><td>Endonuclease inhibitor</td><td>Baloxavir marboxil</td><td>Influenza up to 48&#x000a0;h in duration in patients 12&#x000a0;years of age or older</td><td>No significant side effects described</td><td>Single-dose completes the course of treatment, avoid co administration with antacids, laxatives, or oral supplements</td></tr><tr><td>Non-nucleoside reverse transcriptase inhibitor</td><td>Doravirine</td><td>Combination therapy for HIV infection</td><td>Uncommon; immune reconstitution inflammatory syndrome</td><td>Do not co-administer strong cytochrome P450 enzyme inducers</td></tr><tr><td>Monoclonal anti MDR HIV antibody</td><td>Ibalizumab-uiyk</td><td>MDR HIV infection</td><td>Diarrhea, rash; immune reconstitution inflammatory syndrome</td><td/></tr><tr><td>Anti-hepatitis C combination drug</td><td>Glecaprevir and pibrentasvir</td><td>Hepatitis C infection</td><td>Reactivation of hepatitis B that can result in fulminant hepatitis; worsening liver failure;</td><td>Contraindicated in patients with severe liver impairment; avoid co-administering strong cytochrome P450 enzyme inducers</td></tr><tr><td>Anti-hepatitis C combination drug</td><td>Sofosbuvir/velpatasvir/voxilaprevir</td><td>Hepatitis C infection</td><td>Reactivation of hepatitis B that can result in fulminant hepatitis, case reports of severe bradycardia when amiodarone is co-administered; headache</td><td>Not recommended in patients with moderate to severe hepatic impairment; do not co administer rifampin;</td></tr></tbody></table></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Select new indications for old antibiotics [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Name</th><th>Explored new indications</th><th>Comments</th></tr></thead><tbody><tr><td>Gentamicin, kanamycin</td><td><italic>N. gonorrhoeae</italic> infections</td><td/></tr><tr><td>Ertapenem</td><td><italic>N. gonorrhoeae</italic> infections</td><td/></tr><tr><td>Fosfomycin</td><td><italic>N. gonorrhoeae</italic> infections</td><td/></tr><tr><td>Spectinomycin</td><td><italic>N. gonorrhoeae</italic> infections</td><td>First developed in 1960, abandoned after resistance emerged and new agents appeared, used again in some European countries, China, and South Korea [<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td>Ramoplanin</td><td><italic>Clostridium difficile</italic></td><td>Not absorbed from oral administration</td></tr><tr><td>Minocycline</td><td>MRSA</td><td/></tr><tr><td>Mecillinam [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td>MDR Enterobacteriaceae</td><td>Not available in the USA</td></tr><tr><td>Tetracyclines, &#x003b2;-lactams, microcyclics</td><td>Neuroprotection in Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>Exploring anti-inflammatory properties</td></tr><tr><td>Nebulized antibiotics formulations</td><td>Amikacin, ciprofloxacin for ventilator-associated pneumonia [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td>Currently only colistin, aztreonam, and tobramycin improved for use exclusively in patients with cystic fibrosis</td></tr></tbody></table></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Select novel antibiotics in development [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] Google Scholar search</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug class</th><th>Names and notes</th><th>Indications</th><th>Comments</th></tr></thead><tbody><tr><td>Defensins [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>Brilacidin</td><td>Broad-spectrum antibacterial activity</td><td/></tr><tr><td>Medicinal leech and other animal venom as source for antimicrobial peptides [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]</td><td>Several peptides are studied</td><td/><td>Interest based on ability of leech to store blood for a long time</td></tr><tr><td>Extremophile bacteria as sources of antibiotics [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]</td><td/><td/><td>Fusaricidin B isolated from hot spring&#x02013;derived bacteria is assigned a new application for tuberculosis treatment</td></tr><tr><td>Fluoroketolides</td><td>Solithromycin [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>Activity against <italic>N. gonorrhoeae</italic>, <italic>C. trachomatis</italic>, <italic>M. genitalium</italic>, and Gram-positive respiratory pathogens</td><td/></tr><tr><td>Spiropyrimidinetrione topoisomerase II inhibitor</td><td>Zoliflodacin</td><td>Activity against XDR <italic>N. gonorrhoeae</italic> and C. trachomatis</td><td/></tr><tr><td>Triazaacenaphthylenes</td><td>Gepotidacin</td><td>Activity against MRSA, ESBL Enterobacteriaceae, and <italic>N. gonorrhoeae</italic></td><td/></tr><tr><td>Cephalosporin/vancomycin heterodimer</td><td>Cefilavancin</td><td>Gram-positive pathogens</td><td/></tr><tr><td>Ethambutol</td><td>SQ 109</td><td><italic>M. tuberculosis</italic></td><td/></tr><tr><td>Non-absorbable small molecule antibiotic</td><td>Ridinilazole</td><td><italic>Clostridium difficile</italic> all strains</td><td>Granted fast track status by FDA</td></tr><tr><td>Polymixins [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>NAB741, CB-182804</td><td>Gram negatives</td><td>Early stages</td></tr><tr><td>Peptidomimetic</td><td>Murepavadin [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]</td><td><italic>P. aeruginosa</italic> infections</td><td>Novel mechanism of action pseudomonas specific</td></tr><tr><td>Carbapenems</td><td>Tebipenem [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td>Broad spectrum</td><td>First carbapenem with oral formulation available</td></tr><tr><td>Fluoroquinolones</td><td>Nemonoxacin; zabofloxacin</td><td>Broad spectrum with anti MRSA activity</td><td>Approved and used in several countries</td></tr><tr><td>Boronic acids</td><td>RPX7009 [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td/><td>B-Lactamase inhibitors</td></tr></tbody></table></table-wrap></p></sec></body><back><fn-group><fn><p>This article is part of the Topical collection on <italic>Infectious Disease</italic></p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors wish to thank Dr. David Effron for reviewing their manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#x02022; Of importance &#x02022;&#x02022; Of major importance</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacconelli</surname><given-names>E</given-names></name><name><surname>Carrara</surname><given-names>E</given-names></name><name><surname>Savoldi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>3</issue><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30753-3</pub-id><pub-id pub-id-type="pmid">29276051</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieri</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Boutin</surname><given-names>A</given-names></name></person-group><article-title>Antibiotic resistance</article-title><source>J Infect Public Health</source><year>2017</year><volume>10</volume><issue>4</issue><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2016.08.007</pub-id><pub-id pub-id-type="pmid">27616769</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazer-Amirshahi</surname><given-names>M</given-names></name><name><surname>Pourmand</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>L</given-names></name></person-group><article-title>Newly approved antibiotics and antibiotics reserved for resistant infections: implications for emergency medicine</article-title><source>Am J Emerg Med</source><year>2017</year><volume>35</volume><issue>1</issue><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2016.10.034</pub-id><pub-id pub-id-type="pmid">28029487</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Galvin</surname><given-names>HD</given-names></name><name><surname>Haw</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Drug resistance in influenza A virus: the epidemiology and management</article-title><source>Infect Drug Resist</source><year>2017</year><volume>10</volume><fpage>121</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.2147/IDR.S105473</pub-id><pub-id pub-id-type="pmid">28458567</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banin</surname><given-names>E</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Kuipers</surname><given-names>OP</given-names></name></person-group><article-title>Editorial: Bacterial pathogens, antibiotics and antibiotic resistance</article-title><source>FEMS Microbiol Rev</source><year>2017</year><volume>41</volume><issue>3</issue><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1093/femsre/fux016</pub-id><pub-id pub-id-type="pmid">28486583</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnham</surname><given-names>JP</given-names></name><name><surname>Olsen</surname><given-names>MA</given-names></name><name><surname>Kollef</surname><given-names>MH</given-names></name></person-group><article-title>Re-estimating annual deaths due to multidrug-resistant organism infections</article-title><source>Infect Control Hosp Epidemiol</source><year>2019</year><volume>40</volume><issue>1</issue><fpage>112</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1017/ice.2018.304</pub-id><pub-id pub-id-type="pmid">30463634</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourmand</surname><given-names>A</given-names></name><name><surname>Mazer-Amirshahi</surname><given-names>M</given-names></name><name><surname>Jasani</surname><given-names>G</given-names></name></person-group><article-title>Emerging trends in antibiotic resistance: implications for emergency medicine</article-title><source>Am J Emerg Med</source><year>2017</year><volume>35</volume><issue>8</issue><fpage>1172</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2017.03.010</pub-id><pub-id pub-id-type="pmid">28302376</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shane</surname><given-names>AL</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>PJ</given-names></name><name><surname>Stoll</surname><given-names>BJ</given-names></name></person-group><article-title>Neonatal sepsis</article-title><source>Lancet</source><year>2017</year><volume>390</volume><issue>10104</issue><fpage>1770</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31002-4</pub-id><pub-id pub-id-type="pmid">28434651</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>O</given-names></name><name><surname>Kenny</surname><given-names>CB</given-names></name><name><surname>Goel</surname><given-names>N</given-names></name></person-group><article-title>Neonatal sepsis</article-title><source>Paediatr Child Health</source><year>2019</year><volume>29</volume><issue>6</issue><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.paed.2019.03.003</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koszalka</surname><given-names>P</given-names></name><name><surname>Tilmanis</surname><given-names>D</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name></person-group><article-title>Influenza antivirals currently in late-phase clinical trial</article-title><source>Influenza Other Respir Viruses</source><year>2017</year><volume>11</volume><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/irv.12446</pub-id><pub-id pub-id-type="pmid">28146320</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ison</surname><given-names>MG</given-names></name></person-group><article-title>Antiviral treatments</article-title><source>Clin Chest Med</source><year>2017</year><volume>38</volume><issue>1</issue><fpage>139</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2016.11.008</pub-id><pub-id pub-id-type="pmid">28159156</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Fangman Chen Hao Xu Jinli Liu etc Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta&#x02010;analysis J Oral Pathol Med 2017;46:561&#x02013;568</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Kristen M, Bullard-Feibelman, Jennifer Govero, ZheZhu etc The FDA-approved drug sofosbuvir inhibits Zika virus infection Antiviral Research Vol. 137. 2017;137:134&#x02013;140</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedict</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>M</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name></person-group><article-title>Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>12</issue><fpage>403</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30443-7</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campoy</surname><given-names>S</given-names></name><name><surname>Adrio</surname><given-names>JL</given-names></name></person-group><article-title>Antifungals</article-title><source>Biochem Pharmacol</source><year>2017</year><volume>133</volume><fpage>86</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.11.019</pub-id><pub-id pub-id-type="pmid">27884742</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlin</surname><given-names>DS</given-names></name><name><surname>Rautemaa-Richardson</surname><given-names>R</given-names></name><name><surname>Alastruey-Izquierdo</surname><given-names>A</given-names></name></person-group><article-title>The global problem of antifungal resistance: prevalence, mechanisms, and management</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><issue>12</issue><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30316-X</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T</given-names></name></person-group><article-title>Update on pediatric sepsis: a review</article-title><source>J Intensive Care</source><year>2017</year><volume>5</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s40560-017-0240-1</pub-id><pub-id pub-id-type="pmid">28729906</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>M</given-names></name><name><surname>DeMott</surname><given-names>JM</given-names></name><name><surname>Hallock</surname><given-names>M</given-names></name></person-group><article-title>Systemic antibiotics for the treatment of skin and soft tissue abscesses: a systematic review and meta-analysis</article-title><source>Ann Emerg Med</source><year>2019</year><volume>73</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2018.02.011</pub-id><pub-id pub-id-type="pmid">29530658</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>P</given-names></name><name><surname>Martens</surname><given-names>E</given-names></name></person-group><article-title>Antibiotics in late clinical development</article-title><source>Biochem Pharmacol</source><year>2017</year><volume>133</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.025</pub-id><pub-id pub-id-type="pmid">27687641</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>ND</given-names></name><name><surname>Temkin</surname><given-names>E</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name></person-group><article-title>The negative impact of antibiotic resistance</article-title><source>Clin Microbiol Infect</source><year>2016</year><volume>22</volume><issue>5</issue><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.12.002</pub-id><pub-id pub-id-type="pmid">26706614</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>J</given-names></name><name><surname>Prat</surname><given-names>D</given-names></name><name><surname>Sztrymf</surname><given-names>B</given-names></name></person-group><article-title>Linezolid versus vancomycin in Methicillin Resistant <italic>Staphylococcus aureus</italic> nosocomial pneumonia in the elderly</article-title><source>Am J Emerg Med</source><year>2017</year><volume>35</volume><issue>8</issue><fpage>1197</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2017.05.043</pub-id><pub-id pub-id-type="pmid">28576638</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imani</surname><given-names>S</given-names></name><name><surname>Buscher</surname><given-names>H</given-names></name><name><surname>Marriott</surname><given-names>D</given-names></name><etal/></person-group><article-title>Too much of a good thing: a retrospective study of &#x003b2;-lactam concentration&#x02013;toxicity relationships</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><issue>10</issue><fpage>2891</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx209</pub-id><pub-id pub-id-type="pmid">29091190</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alirol</surname><given-names>E</given-names></name><name><surname>Wi</surname><given-names>TE</given-names></name><name><surname>Bala</surname><given-names>M</given-names></name><name><surname>Bazzo</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>X-S</given-names></name><name><surname>Deal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines</article-title><source>PLoS Med</source><year>2017</year><volume>14</volume><issue>7</issue><fpage>e1002366</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1002366</pub-id><pub-id pub-id-type="pmid">28746372</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for <italic>Clostridium difficile</italic>-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3).</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><article-title>Antibiotics in the clinical pipeline at the end of 2015</article-title><source>J Antibiot</source><year>2017</year><volume>70</volume><fpage>3</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.72</pub-id><pub-id pub-id-type="pmid">27353164</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><name><surname>Huttner</surname><given-names>A</given-names></name></person-group><article-title>New and improved? a review of novel antibiotics for Gram-positive bacteria</article-title><source>Clin Microbiol Infect</source><year>2017</year><volume>23</volume><issue>10</issue><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2017.06.010</pub-id><pub-id pub-id-type="pmid">28642145</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>MZ</given-names></name><name><surname>Dryden</surname><given-names>M</given-names></name><name><surname>Gottlieb</surname><given-names>T</given-names></name><etal/></person-group><article-title>Recently approved antibacterials for methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and other Gram-positive pathogens: the shock of the new</article-title><source>Int J Antimicrob Agents</source><year>2017</year><volume>50</volume><issue>3</issue><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.05.006</pub-id><pub-id pub-id-type="pmid">28666751</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Vena</surname><given-names>A</given-names></name><name><surname>Castaldo</surname><given-names>N</given-names></name></person-group><article-title>New antibiotics for ventilator-associated pneumonia</article-title><source>Curr Opin Infect Dis</source><year>2018</year><volume>31</volume><issue>2</issue><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000438</pub-id><pub-id pub-id-type="pmid">29337703</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocheretyaner</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and <italic>Pseudomonas aeruginosa</italic></article-title><source>Expert Rev Anti-Infect Ther</source><year>2018</year><volume>16</volume><issue>7</issue><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1080/14787210.2018.1489721</pub-id><pub-id pub-id-type="pmid">29911455</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Cefiderocol: a novel siderophore cephalosporin</article-title><source>Expert Opin Investig Drugs</source><year>2018</year><volume>27</volume><issue>2</issue><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1080/13543784.2018.1426745</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bass&#x000e8;res</surname><given-names>E</given-names></name><name><surname>Endres</surname><given-names>BT</given-names></name><name><surname>Dotson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Novel antibiotics in development to treat <italic>Clostridium difficile</italic> infection</article-title><source>Curr Opin Gastroenterol</source><year>2017</year><volume>33</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/MOG.0000000000000332</pub-id><pub-id pub-id-type="pmid">28134686</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zayyad</surname><given-names>H</given-names></name><name><surname>Eliakim-Raz</surname><given-names>N</given-names></name><name><surname>Leibovici</surname><given-names>L</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name></person-group><article-title>Revival of old antibiotics: needs, the state of evidence and expectations</article-title><source>Int J Antimicrob Agents</source><year>2017</year><volume>49</volume><issue>5</issue><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.11.021</pub-id><pub-id pub-id-type="pmid">28162982</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reglodi</surname><given-names>D</given-names></name><name><surname>Renaud</surname><given-names>J</given-names></name><name><surname>Tamas</surname><given-names>A</given-names></name></person-group><article-title>Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides</article-title><source>Prog Neurobiol</source><year>2017</year><volume>155</volume><fpage>120</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.10.004</pub-id><pub-id pub-id-type="pmid">26542398</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>B</given-names></name><name><surname>Reiling</surname><given-names>S</given-names></name><name><surname>Zarena</surname><given-names>D</given-names></name><etal/></person-group><article-title>Host defense antimicrobial peptides as antibiotics: design and application strategies</article-title><source>Curr Opin Chem Biol</source><year>2017</year><volume>38</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2017.03.014</pub-id><pub-id pub-id-type="pmid">28399505</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grafskaia</surname><given-names>EN</given-names></name><name><surname>Nadezhdin</surname><given-names>KD</given-names></name><name><surname>Talyzina</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Medicinal leech antimicrobial peptides lacking toxicity represent a promising alternative strategy to combat antibiotic-resistant pathogens</article-title><source>Eur J Med Chem</source><year>2019</year><volume>180</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.06.080</pub-id><pub-id pub-id-type="pmid">31302447</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demain</surname><given-names>AL</given-names></name><name><surname>G&#x000f3;mez-Ortiz</surname><given-names>B</given-names></name><name><surname>Ruiz-Villaf&#x000e1;n</surname><given-names>B</given-names></name><etal/></person-group><article-title>Recent findings of molecules with anti-infective activity: screening of non-conventional sources</article-title><source>Curr Opin Pharmacol</source><year>2019</year><volume>48</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2019.04.003</pub-id><pub-id pub-id-type="pmid">31078095</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>GB</given-names></name><name><surname>Balachandran</surname><given-names>L</given-names></name></person-group><article-title>Sources of antibiotics: hot springs</article-title><source>Biochem Pharmacol</source><year>2017</year><volume>134</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.11.021</pub-id><pub-id pub-id-type="pmid">27890726</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Dawson</surname><given-names>MJ</given-names></name></person-group><article-title>Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections</article-title><source>J Antibiot</source><year>2017</year><volume>70</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.146</pub-id><pub-id pub-id-type="pmid">28074057</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Loeches</surname><given-names>I</given-names></name><name><surname>Dale</surname><given-names>GE</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Murepavadin: a new antibiotic class in the pipeline</article-title><source>Expert Rev Anti-Infect Ther</source><year>2018</year><volume>16</volume><issue>4</issue><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1080/14787210.2018.1441024</pub-id><pub-id pub-id-type="pmid">29451043</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Utley</surname><given-names>L</given-names></name><name><surname>Parr</surname><given-names>TR</given-names></name><name><surname>Zabawa</surname><given-names>T</given-names></name><name><surname>Pucci</surname><given-names>MJ</given-names></name></person-group><article-title>Tebipenem, the first oral carbapenem antibiotic</article-title><source>Expert Rev Anti-Infect Ther</source><year>2018</year><volume>16</volume><issue>7</issue><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1080/14787210.2018.1496821</pub-id><pub-id pub-id-type="pmid">30014729</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Bello</surname><given-names>C</given-names></name></person-group><article-title>Recently developed synthetic compounds with anti-infective activity</article-title><source>Curr Opin Pharmacol</source><year>2019</year><volume>48</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2019.03.004</pub-id><pub-id pub-id-type="pmid">31005786</pub-id></element-citation></ref></ref-list></ref-list></back></article>